A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
Status:
Not yet recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
This is a double-blind, saline-controlled, and randomized study with blinded assessments
using a single dose. Subjects that have a current diagnosis of chronic lumbar disc disease
and meet eligibility criteria will be enrolled.